Comparative Pharmacology
Head-to-head clinical analysis: BRISTAGEN versus NEOMYCIN SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRISTAGEN versus NEOMYCIN SULFATE.
BRISTAGEN vs NEOMYCIN SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bristagen (amikacin) is an aminoglycoside antibiotic that irreversibly binds to the 30S ribosomal subunit, inhibiting bacterial protein synthesis.
Aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and causing bacterial cell death by disrupting the cytoplasmic membrane.
1-2 mg/kg IM or IV every 8-12 hours; typical adult dose is 1 mg/kg every 8 hours.
1-2 g orally 4 times daily (8-16 g/day) for hepatic encephalopathy or intraluminal infection; 0.5-1 g orally 4 times daily for preoperative bowel preparation.
None Documented
None Documented
2.5 hours (prolonged to 20-40 hours in renal impairment).
2-3 hours (normal renal function); prolonged to 20-60 hours in anuria
Renal (90% unchanged via glomerular filtration); biliary/fecal excretion <10%.
Renal (glomerular filtration) >90% unchanged; small amount biliary/fecal (<3%)
Category C
Category A/B
Aminoglycoside Antibiotic
Aminoglycoside Antibiotic